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Characteristic Subcategory All (n=201) DNA sample 
available 
(n=118, 58.7%) 
DNA sample not 
available 
(n=83, 41.3%) 








Age – median years (IQR) 

























Province of origin, n (%) Madang Province 







































BMI – median (IQR)  18.5 (16.3-21.1) 17.4 (15.9-21.4) 19.6 (16.8-21.4) 



















































































Associations with M. 
tuberculosis Lineage 2 




OR (95% CI) p-value 















Age – median years (IQR) 26 (20-31) 28 (21-34) 1.0 (0.9-1.1) 0.79 
PNG province of origin, n (%) 
 Madang 
























































































































































































































□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ 1 Beijing 38 (22.0) Lineage 2 
49 (22.5) ■■■■■■■■■■■■■■□□■■■■■■■■■■■■■■■■■■■■■■■■■■■ - Orphan 1 (0.6) 
Lineage 1 
1 (0.6) 


























 Lineage 4 (%) 
n=12 




















































































resistance to >1 drug 




OR (95% CI) p-value 















Age – median years (IQR) 25 (20-30) 29 (24-35) 1.0 (1.0-1.1) 0.05 
PNG province of origin, n (%) 
 Madang 














































Strain lineage, n (%) 
 *Lineage 4 














































































Associations with molecularly 
clustered strains  




OR (95% CI) p-value 















Age – median years (IQR) 26 (20-30) 26 (21-34) 1.0 (1.0-1.1) 0.42 
PNG province of origin, n (%) 
 Madang 














































Strain lineage, n (%) 
 *Lineage 4 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1 RIF monoresistant                
2 INH monoresistant               
3 INH monoresistant               
4 INH monoresistant               
5 INH monoresistant               
6 INH monoresistant               
7 INH monoresistant               
8 INH monoresistant               
9 INH monoresistant               
10 INH monoresistant               
11 STR monoresistant               
12 STR monoresistant               
13 STR monoresistant               
14 STR monoresistant               
15 PZA monoresistant               
16 INH + STR polyresistant               
17 INH + STR polyresistant               
18 INH + STR polyresistant               
19 RIF + INH MDR               
20 RIF + INH MDR               
21 RIF + INH MDR               
22 RIF + INH MDR               
23 RIF + INH MDR               
24 RIF + INH + ETH MDR               
25 RIF + INH + ETH MDR               
26 RIF + INH + ETH + STR MDR               










































Gene Direction Primer sequence (5’-3’) PCR conditions 
Product 
length (bp) Reference 
rpoB Rv0667 Forward TCGGCGAGCTGATCCAAAACCA Tm: 62°C, Ex: 
45, Cy: 35 
601 This study 
rpoB Rv0667 Reverse ACGTCCATGTAGTCCACCTCAG   This study 
inhA (promoter) Rv1484 Forward GGCACGTACACGTCTTTATGTA Tm: 60°C, Ex: 
30, Cy: 35 
478 [1] 
inhA (promoter) Rv1484 Reverse GGTGCTCTTCTACCGCCGTGAA   [1] 
katG Rv1908c Forward CCAGCGGCCCAAGGTATC Tm: 64°C, Ex: 
60, Cy: 35 
850 This study 
katG Rv1908c Reverse GCTGTGGCCGGTCAAGAAGAAGTA   This study 
ahpC 
(promoter) 
Rv2428 Forward ACCACTGCTTTGCCGCCACC Tm: 64°C, Ex: 




Rv2428 Reverse CCGATGAGAGCGGTGAGCTG   [2] 
embB Rv3795 Forward CGGCATGCGCCGGCTGATTC Tm: 65°C, Ex: 
30, Cy: 35 
260 [3] 
embB Rv3795 Reverse TCCACAGACTGGCGTCGCTG   [3] 
gyrA Rv0006 Forward CAGCTACATCGACTATGCG Tm: 58°C, Ex: 
30, Cy: 35 
320 [4] 
gyrA Rv0006 Reverse GGCTTCGGTGTACCTCATC   Adapted from [4] 
gidB Rv3919c Forward CGAGAGCGGAGAATGTTTCAC Tm: 60°C, Ex: 
60, Cy: 35 
793 This study 
gidB Rv3919c Reverse CTGGCCCGACCTTACGAGC   This study 
rpsL Rv0682 Forward CGTGAAAGCGCCCAAGATAG Tm: 62°C, Ex: 
30, Cy: 35 
333 This study 
rpsL Rv0682 Reverse GAACCGCGGATGATCTTGTAG   Adapted from [5] 
rrs MTB000033 Forward GATGACGGCCTTCGGGTTGT Tm: 60°C, Ex: 
30, Cy: 35 
238 [5]  
rrs MTB000033 Reverse TCTAGTCTGCCCGTATCGCC   [5] 
rrs MTB000033 Forward GTAGTCCACGCCGTAAACGG Tm: 60°C, Ex: 
30, Cy: 35 
245 [5] 
rrs MTB000033 Reverse CACACAGGCCACAAGGGAAC   Adapted from [5] 
rrs MTB000033 Forward CGTTCCCTTGTGGCCTGTG Tm: 62°C, Ex: 
45, Cy: 35 
547 This study 
rrs MTB000033 Reverse GGCGTTTTCGTGGTGCTCC   Adapted from [5]  
pncA Rv2043c Forward GGCTGCCGCGTCGGTAGG Tm: 62°C, Ex: 
45, Cy: 35 
652 This study 
pncA Rv2043c Reverse GCCGCCAACAGTTCATCCC   This study All	
   PCRs	
  were	
  performed	
  using	
  FastStart	
  Taq	
  DNA	
  Polymerase	
   and	
   the	
   corresponding	
  buffers	
  (Roche	
   Diagnostics,	
   Switzerland).	
   Tm:	
   Annealing	
   temperature,	
   Ex:	
   Extension	
   time	
   (seconds),	
   Cy:	
  number	
  of	
  cycles.	
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  discussion	
  
Synopsis	
  of	
  findings	
  The	
   aim	
   of	
   this	
   thesis	
   was	
   to	
   provide	
   so	
   far	
   missing	
   but	
   necessary	
   information	
   about	
   the	
  characteristics	
  of	
  M.	
  tuberculosis	
   strains	
  circulating	
   in	
  PNG,	
  with	
   focus	
  on	
  the	
  Madang	
  region.	
  The	
  analyses	
   of	
   patient	
   sputum	
   isolates	
   collected	
   in	
   this	
   area	
   indicated	
   substantial	
   rates	
   of	
   drug-­‐resistant	
  TB.	
  Overall,	
  15.7%	
  of	
  the	
  strains	
  were	
  resistant	
  to	
  at	
  least	
  one	
  drug	
  and	
  5.2%	
  were	
  MDR.	
  Furthermore,	
   the	
   genotyping	
   of	
   these	
   strains	
   indicated	
   the	
   presence	
   of	
   two	
   predominant	
   M.	
  
tuberculosis	
   lineages:	
   about	
   three	
   quarters	
   Euro-­‐American	
   lineage	
   (i.e.	
   Lineage	
   4)	
   and	
   about	
   one	
  quarter	
  East-­‐Asian	
  lineage	
  (i.e.	
  Lineage	
  2).	
  Samples	
  of	
  the	
  East-­‐Asian	
  lineage	
  were	
  more	
  often	
  found	
  to	
  be	
  associated	
  with	
  drug	
  resistance,	
  as	
  previously	
  observed.	
  The	
  lineages	
  were	
  sub-­‐divided	
  into	
  distinct	
   spoligotypes.	
   While	
   Lineage	
   2	
   was	
   composed	
   of	
   two	
   different	
   spoligotypes,	
   Lineage	
   4	
  comprised	
  31	
  different	
   spoligotypes,	
   thus	
   illustrating	
   the	
  actual	
  diversity	
   that	
  M.	
   tuberculosis	
   can	
  harbor.	
  This	
  diversity	
  was	
  used	
  to	
  define	
  molecular	
  clusters	
  of	
  M.	
  tuberculosis	
  strains	
  by	
  combining	
  the	
   DNA	
   fingerprints	
   obtained	
   from	
   spoligotyping	
   and	
   from	
   24-­‐locus	
   MIRU-­‐VNTR	
   typing.	
   We	
  observed	
  that	
  44.4%	
  of	
  the	
  strains	
  shared	
  identical	
  DNA	
  genotypes,	
  suggesting	
  evidence	
  for	
  recent	
  transmission.	
   Furthermore,	
   25.0%	
   of	
   the	
   clusters	
   included	
   drug-­‐resistant	
   strains,	
   indicating	
   that	
  these	
  are	
  circulating	
  in	
  the	
  community	
  as	
  well.	
  	
  
Study	
  design	
  This	
  study	
  was	
  launched	
  in	
  2007-­‐2008	
  when	
  the	
  PNG	
  national	
  TB	
  program	
  asked	
  the	
  PNG	
  IMR	
  to	
   initiate	
  research	
  on	
  TB	
  with	
  the	
  main	
  goal	
  of	
  describing	
  the	
  extent	
  of	
  disease	
  burden	
  and	
  drug	
  resistance.	
  Bringing	
  their	
  respective	
  expertise	
  together,	
  the	
  PNG	
  IMR	
  and	
  the	
  Swiss	
  TPH	
  embarked	
  on	
  this	
  TB	
  project,	
  combining	
  research	
  and	
  capacity	
  transfer	
  objectives	
  in	
  a	
  sustainable	
  way.	
  
Capacity	
  transfer	
  The	
   transfer	
  of	
  capacity	
  was	
  a	
  primordial	
  component	
  of	
   this	
   thesis,	
  especially	
  at	
   its	
  beginning.	
  Indeed,	
   the	
   results	
   presented	
   here	
   would	
   not	
   have	
   been	
   obtained	
   without	
   the	
   adequate	
   work	
  performed	
  at	
   the	
  TB	
   laboratory	
   in	
  Madang.	
  Time	
  was	
   therefore	
   invested	
   in	
   training	
   local	
  staff,	
   so	
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that	
  this	
  laboratory	
  could	
  sustainably	
  support	
  TB	
  activities	
  in	
  the	
  region.	
  The	
  primary	
  objective	
  was	
  to	
   implement	
   routine	
   mycobacteriological	
   techniques	
   for	
   the	
   manipulation	
   of	
   patient	
   sputum	
  samples	
  collected	
  at	
  Modilon	
  General	
  Hospital	
  and	
  other	
  collaborating	
  health	
  centers	
  in	
  the	
  region.	
  For	
  this	
  purpose,	
   two	
  visits	
  were	
  scheduled	
  to	
  Madang,	
  during	
  which	
  the	
  Swiss	
  TPH	
  and	
  the	
  PNG	
  IMR	
  collaborators	
  have	
  set	
  up	
  the	
  necessary	
   infrastructures	
  and	
  protocols.	
  Although	
  this	
  capacity	
  transfer	
   component	
   required	
   time	
   investment	
   far	
   beyond	
   the	
   two	
   visit	
   periods	
   and	
   arguably	
  reduced	
  the	
  time	
  allocated	
  to	
  analyses	
  and	
  possibly	
  the	
  amount	
  of	
  results	
  obtained	
  for	
  the	
  present	
  thesis,	
  it	
  was	
  an	
  absolute	
  prerequisite	
  to	
  this	
  project	
  and	
  was	
  considered	
  on	
  its	
  own	
  as	
  part	
  of	
  the	
  thesis.	
  	
  
Study	
  site	
  The	
  newly	
   available	
   laboratory	
   offered	
   a	
   unique	
   opportunity	
   to	
   initiate	
   the	
   present	
   project	
   in	
  Madang.	
   Indeed,	
   apart	
   from	
   one	
   laboratory	
   in	
   Port	
   Moresby,	
   the	
   capital	
   city	
   of	
   PNG,	
   no	
   other	
  laboratory	
   in	
   PNG	
   was	
   equipped	
   for	
   sputum	
   handling	
   and	
   therefore,	
   the	
   building	
   of	
   these	
   new	
  facilities	
  was	
  decisive	
  for	
  the	
  initiation	
  of	
  the	
  study	
  in	
  Madang.	
  Furthermore,	
  this	
  project	
  was	
  made	
  possible	
  by	
  the	
  availability	
  of	
  a	
  local	
  medical	
  team	
  willing	
  to	
  get	
  involved	
  and	
  support	
  this	
  project	
  on	
   a	
   long	
   term	
   basis.	
   However,	
   because	
   strain	
   culture	
   cannot	
   be	
   done	
   in	
   a	
   biosafety	
   level	
   2	
  laboratory,	
  the	
  QMRL	
  (in	
  Australia)	
  was	
  involved	
  in	
  the	
  study	
  for	
  the	
  culture	
  and	
  phenotypic	
  DST	
  on	
  all	
  collected	
  isolates.	
  The	
   size	
   and	
   importance	
  of	
   the	
  Modilon	
  General	
  Hospital	
   for	
  Madang	
  and	
   surroundings	
   could	
  ensure	
  that	
  active	
  TB	
  patients	
  would	
  primarily	
  seek	
  care	
  in	
  this	
  hospital.	
  Nevertheless,	
  one	
  cannot	
  exclude	
   that	
   this	
   created	
   a	
   bias	
   towards	
   possibly	
   sicker	
   individuals	
   and	
   thereby	
   higher	
   rates	
   of	
  MDR-­‐TB.	
   To	
   confirm	
   this	
   possible	
   bias,	
   data	
   from	
   longitudinal	
   drug	
   resistance	
   monitoring	
   and	
  multi-­‐site	
   comparisons	
   of	
   drug	
   resistance	
   rates	
   in	
   PNG	
  would	
   be	
   needed.	
   Furthermore,	
   it	
   is	
   also	
  possible	
  that	
  the	
  proximity	
  of	
  the	
  newly	
  available	
  laboratory	
  and	
  the	
  initiation	
  of	
  the	
  present	
  study	
  influenced	
   the	
   suspicion	
   for	
   TB	
   among	
   both	
   the	
   patients	
   and	
   the	
   medical	
   staff	
   in	
   that	
   region.	
  However,	
  if	
  the	
  latter	
  is	
  true,	
  we	
  can	
  suppose	
  that	
  this	
  did	
  not	
  necessarily	
  bias	
  the	
  study	
  population	
  towards	
  only	
  sicker	
  individuals.	
  Knowing	
   that	
   the	
   Modilon	
   General	
   Hospital	
   is	
   the	
   most	
   important	
   hospital	
   in	
   the	
   region	
   of	
  Madang,	
   a	
   fairly	
   large	
  number	
  of	
  TB	
  patients	
  was	
   expected	
   (about	
  300	
  patients	
  per	
   year).	
   In	
   the	
  end,	
  the	
  number	
  of	
  patients	
  included	
  in	
  the	
  study	
  period	
  was	
  lower,	
  with	
  about	
  200	
  pulmonary	
  TB	
  patients	
  recruited	
  between	
  April	
  2009	
  and	
  October	
  2010.	
  Although	
  we	
  do	
  not	
  have	
  an	
  explanation	
  for	
   this,	
   we	
   speculate	
   that	
   various	
   factors	
   could	
   influence	
   the	
   number	
   of	
   pulmonary	
   patients	
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observed	
  in	
  the	
  frame	
  of	
  this	
  study.	
  It	
  could	
  well	
  be	
  that	
  pulmonary	
  TB	
  is	
  not	
  that	
  frequent	
  in	
  this	
  region.	
   Nevertheless,	
   the	
   existence	
   of	
   molecularly	
   clustered	
  M.	
   tuberculosis	
   strains	
   suggests	
   that	
  tubercle	
  bacilli	
  might	
  be	
  circulating	
  in	
  the	
  population,	
  and	
  that	
  at	
  least	
  part	
  of	
  the	
  observed	
  active	
  TB	
   cases	
   likely	
   resulted	
   from	
   recent	
   transmission.	
   Another	
   factor	
   could	
   be	
   related	
   to	
   the	
   study	
  design	
   (also	
   discussed	
   below),	
   which	
   in	
   this	
   situation	
   was	
   based	
   on	
   the	
   passive	
   detection	
   of	
  suspected	
   TB	
   patients	
   seeking	
   care.	
   This	
   approach	
   relies	
   largely	
   on	
   the	
   awareness	
   of	
   TB	
   in	
   the	
  population,	
  which	
  may	
  not	
  be	
  equal	
   everywhere.	
  Although	
  more	
   specific	
   investigations	
  would	
  be	
  necessary	
  to	
  address	
  this	
  point,	
  one	
  could	
  speculate	
  that	
  TB	
  awareness	
  may	
  for	
  example	
  depend	
  on	
  the	
   patients’	
   living	
   place,	
   level	
   of	
   education,	
   socio-­‐economic	
   status,	
   religion	
   and	
   other	
   beliefs.	
  Furthermore,	
  the	
  symptoms	
  of	
  active	
  TB	
  are	
  not	
  particularly	
  specific	
  and	
  may	
  be	
  mistaken	
  for	
  less	
  severe	
  conditions,	
  such	
  as	
  cold	
  or	
  flu,	
  which	
  may	
  not	
  lead	
  the	
  patient	
  to	
  seek	
  adequate	
  health	
  care.	
  Lastly,	
   refusal	
   to	
   participate	
   in	
   the	
   study	
   or	
   withdrawals	
   may	
   also	
   have	
   impacted	
   on	
   the	
   final	
  patient	
  number.	
  
Inclusion	
  criteria	
  The	
   inclusion	
   criteria	
   required	
   patients	
   aged	
   above	
   14	
   years	
   with	
   microscopically	
   confirmed	
  pulmonary	
   TB	
   or	
   other	
   clinical	
   evidence	
   suggesting	
   smear-­‐negative	
   TB.	
   The	
   decision	
   of	
   not	
  including	
  younger	
  patients	
  was	
  supported	
  by	
  the	
  fact	
  that	
  children	
  represent	
  a	
  distinct	
  category	
  of	
  patients	
   with	
   less	
   sputum	
   production	
   (making	
   diagnosis	
   difficult)	
   and	
   more	
   frequent	
   extra-­‐pulmonary	
   TB	
   [105].	
   For	
   these	
   two	
   reasons,	
   childhood	
   TB	
   presumably	
   contributes	
   little	
   to	
   TB	
  transmission	
   and	
   is	
   often	
   not	
   primarily	
   investigated.	
   However,	
   including	
   younger	
   pulmonary	
   TB	
  patients	
  in	
  this	
  study	
  could	
  have	
  re-­‐enforced	
  the	
  cohort	
  size,	
  possibly	
  revealing	
  interesting	
  aspects	
  related	
  to	
  the	
  disease	
  outcome	
  or	
  the	
  patient-­‐to-­‐patient	
  transmission,	
  when	
  compared	
  to	
  the	
  adult	
  patients.	
  Smear-­‐negative	
   TB	
   (i.e.	
   culture-­‐confirmed	
   TB	
   patients	
   for	
   whom	
   sputum	
   smear	
   microscopy	
  could	
  not	
  detect	
  any	
  tubercle	
  bacillus)	
  is	
  an	
  important	
  challenge	
  in	
  TB	
  monitoring.	
  The	
  sensitivity	
  of	
   smear	
   microscopy	
   is	
   low	
   (about	
   50-­‐60%	
   or	
   even	
   less	
   in	
   low-­‐income	
   countries	
   [106])	
   and	
  therefore,	
  samples	
  containing	
  bacilli	
  below	
  the	
  level	
  of	
  detection	
  may	
  be	
  classified	
  as	
  TB	
  negative.	
  However,	
   if	
  TB	
   is	
  strongly	
  suspected	
  based	
  on	
  other	
  clinical	
  evidence	
  (for	
  example	
  chest	
  X-­‐ray	
  or	
  chronic	
   cough),	
   the	
   patient	
   can	
   be	
   classified	
   as	
   smear-­‐negative	
   TB	
   and	
   ideally,	
   the	
   presence	
   of	
  mycobacteria	
   should	
   be	
   confirmed	
   by	
   culture.	
   Smear-­‐negative	
   TB	
   is	
   often	
   neglected	
   due	
   to	
   the	
  intrinsic	
   lower	
   risk	
   of	
   transmission,	
   reduced	
   disease	
   extent	
   and	
   good	
   prognosis	
   [106].	
   In	
   the	
  absence	
   of	
   confirmation	
   by	
   in	
   vitro	
   culture,	
   the	
   adequate	
   selection	
   of	
   criteria	
   to	
   define	
   smear-­‐
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negative	
  TB	
  is	
  essential.	
  As	
  an	
  illustration,	
  a	
  study	
  conducted	
  in	
  Zimbabwe	
  indicated	
  that	
  cough	
  for	
  more	
  than	
  three	
  weeks	
  (chronic	
  cough)	
  most	
  likely	
  indicates	
  TB	
  and	
  is	
  therefore	
  a	
  good	
  criterion	
  to	
  select	
  for	
  the	
  diagnosis	
  of	
  smear-­‐negative	
  TB	
  in	
  the	
  absence	
  of	
  culture	
  facilities	
  [107].	
  Interestingly,	
  this	
  study	
  also	
  showed	
  that	
  in	
  this	
  setting,	
  the	
  culture	
  of	
  smear-­‐negative	
  specimens	
  added	
  only	
  little	
  information	
  to	
  the	
  microscopy-­‐based	
  diagnosis.	
  	
  In	
  our	
  study,	
  only	
  a	
  few	
  smear-­‐negative	
  TB	
  patients	
  were	
  included	
  (13	
  smear-­‐negative	
  patients	
  between	
  April	
  2009	
  and	
  October	
  2010,	
  two	
  of	
  them	
  were	
  HIV	
  positive	
  and	
  culture	
  was	
  successful	
  for	
  five	
  of	
  them).	
  Therefore,	
  no	
  particular	
  analysis	
  could	
  be	
  performed	
  on	
  this	
  group	
  of	
  patients	
  in	
  the	
   frame	
  of	
   this	
   thesis.	
   If	
  numbers	
  allowed,	
   it	
  would	
  have	
  been	
   interesting	
   to	
  address	
  questions	
  related	
   to	
   smear-­‐negative	
   TB,	
   for	
   example	
   to	
   validate	
   the	
   clinical	
   suspicion	
   for	
   TB	
   with	
   in	
   vitro	
  culture,	
   to	
   identify	
   the	
   best	
   clinical	
   predictors	
   for	
   TB	
   in	
   case	
   of	
   negative	
   sputum,	
   to	
   see	
   if	
   any	
  patient	
  demographic	
  or	
  clinical	
  characteristic	
   is	
  a	
  risk	
  for	
  smear-­‐negative	
  TB	
  or	
  to	
   investigate	
  the	
  treatment	
  outcomes	
  among	
  these	
  patients.	
  
Study	
  limitations	
  The	
  major	
  limitation	
  of	
  this	
  thesis	
  was	
  the	
  low	
  number	
  of	
  patients	
  included,	
  or	
  more	
  precisely,	
  the	
  low	
  number	
  of	
  samples	
  available	
  for	
  molecular	
  and	
  statistical	
  analyses.	
  Although	
  the	
  TB	
  clinic	
  of	
  the	
  Modilon	
   General	
   Hospital	
  was	
   important	
   enough	
   to	
   attract	
   numerous	
   patients	
   in	
   the	
   region,	
  each	
  manipulation	
  step	
  from	
  the	
  patient	
  sputum	
  collection	
  to	
  the	
  DNA	
  extraction	
  might	
  have	
  been	
  a	
  potential	
   source	
   of	
   error,	
   thereby	
   impacting	
   on	
   the	
   final	
   number	
   of	
   samples	
   available.	
   First,	
   the	
  sputum	
   needed	
   to	
   be	
   stored	
   adequately	
   until	
   decontamination,	
   in	
   order	
   to	
   avoid	
   excessive	
  contamination	
  and	
  to	
  maintain	
  the	
  bacilli	
  viable	
  for	
  culture.	
  The	
  decontamination	
  process	
  aims	
  at	
  killing	
  bacteria	
  other	
  than	
  mycobacteria	
  and	
  present	
  in	
  the	
  sputum,	
  while	
  liquefying	
  the	
  sputum	
  to	
  make	
   most	
   tubercle	
   bacilli	
   accessible.	
   For	
   that,	
   the	
   right	
   balance	
   of	
   reagents	
   is	
   needed	
   and	
   a	
  contamination	
   rate	
   of	
   3–5%	
   is	
   considered	
   as	
   a	
   good	
   balance	
   between	
   killing	
   contaminants	
   and	
  keeping	
  the	
  mycobacteria	
  alive	
  [30].	
  The	
  quality	
  of	
  the	
  reagents	
  and	
  the	
  accuracy	
  of	
  each	
  steps	
  in	
  the	
  protocol	
  are	
  crucial	
  for	
  successful	
  bacterial	
  cultures	
  and	
  ideally,	
  decontaminated	
  sputum	
  should	
  directly	
  be	
   inoculated	
   into	
   the	
  culture	
  medium	
  and	
   incubated.	
  This	
  was	
  unfortunately	
  not	
  always	
  the	
  situation	
   faced	
  by	
  the	
  TB	
   laboratory	
   in	
  Madang.	
  Decontamination	
  might	
  sometimes	
  have	
  only	
  been	
  performed	
  when	
  sufficient	
  numbers	
  of	
  sputum	
  samples	
  were	
  collected	
  and	
  inoculated	
  growth	
  tubes	
  might	
  have	
  been	
  stored	
  until	
  a	
  sufficient	
  number	
  of	
  samples	
  could	
  be	
  shipped	
  to	
  the	
  QMRL.	
  Culture	
  contamination	
  and	
  absence	
  of	
  growth	
  were	
   frequent,	
   and	
  all	
   the	
  above-­‐listed	
  steps	
  could	
  possibly	
   be	
   incriminated.	
   Although	
   some	
   contaminated	
   cultures	
   could	
   be	
   rescued	
   by	
   a	
   second	
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decontamination	
   process	
   to	
   recover	
   living	
   mycobacteria,	
   this	
   was	
   not	
   always	
   successful.	
   In	
  contrast,	
   the	
   absence	
   of	
   growth	
   indicated	
   that	
   viable	
   mycobateria	
   were	
   either	
   killed	
   during	
  decontamination	
  or	
  were	
  in	
  fact	
  absent	
  from	
  the	
  sputum	
  (TB	
  negative	
  patient).	
  In	
  such	
  situations,	
  a	
  second	
   sample	
  would	
   have	
   been	
   necessary	
   for	
   validation,	
   although	
   backup	
   samples	
  were	
  mostly	
  not	
   available.	
   Finally,	
   the	
   method	
   selected	
   for	
   DNA	
   extraction	
   might	
   impact	
   on	
   the	
   final	
   DNA	
  amount	
  and	
  quality.	
  The	
  protocol	
  adopted	
  in	
  this	
  project	
  (i.e.	
  a	
  commercial	
  chelating	
  resin)	
  is	
  fast	
  and	
  easy	
  to	
  perform	
  on	
  grown	
  cultures,	
  but	
  possibly	
  not	
  yielding	
  DNA	
  of	
  high	
  quality.	
  Although	
  this	
  should	
   have	
   been	
   sufficient	
   for	
   PCRs,	
   we	
   observed	
   that	
   some	
   extracts	
   were	
   not	
   amplifiable	
   and	
  therefore	
  not	
  usable	
   for	
  molecular	
   investigations.	
  Other	
  protocols	
  might	
  have	
   improved	
   the	
  DNA	
  quality	
  but	
  would	
  have	
  certainly	
  been	
  more	
  time	
  consuming	
  (and	
  costly)	
  than	
  the	
  selected	
  one.	
  	
  Another	
   limitation	
   of	
   the	
   present	
   study	
  was	
   the	
   absence	
   of	
   contact	
   tracing	
   data,	
   which	
   could	
  have	
  provided	
  useful	
  information	
  for	
  the	
  interpretation	
  of	
  M.	
  tuberculosis	
  transmission.	
  Combining	
  precise	
   contact	
   tracing	
   information	
   with	
   molecular	
   cluster	
   data	
   would	
   have	
   allowed	
   a	
   more	
  accurate	
   evaluation	
   of	
   recent	
   transmission,	
   ensuring	
   that	
   patients	
   infected	
   by	
   M.	
   tuberculosis	
  strains	
   sharing	
   an	
   identical	
   genotype	
  have	
   truly	
  been	
   in	
   contact.	
   Furthermore,	
   elucidating	
  where	
  and	
   how	
   transmission	
   of	
   TB	
   occurred	
   among	
   clusters	
   could	
   have	
   potentially	
   provided	
   useful	
  information	
   to	
   better	
   tackle	
   transmission	
   at	
   these	
   precise	
   occasions.	
   However,	
   contact	
  investigations	
   can	
   be	
   complex,	
   since	
   they	
   imply	
   the	
   identification	
   and	
   assessment	
   of	
   possible	
  contacts	
   of	
   each	
   sputum	
   smear	
   positive	
   TB	
   cases,	
   starting	
   within	
   households	
   and	
   expanding	
   to	
  contacts	
   outside	
   households.	
   Furthermore,	
   ethical	
   considerations	
   play	
   an	
   important	
   role	
   when	
  secondary	
  TB	
  cases	
  are	
  identified	
  [108].	
  Finally,	
  it	
  is	
  possible	
  that	
  an	
  approach	
  based	
  on	
  active	
  case	
  finding	
  would	
  have	
  ensured	
  a	
  larger	
  study	
  population	
  by	
  recruiting	
  active	
  TB	
  patients	
  who	
  may	
  not	
  have	
  come	
  to	
  the	
  clinic	
  otherwise.	
  In	
  fact,	
  this	
  is	
  the	
  approach	
  implemented	
  in	
  the	
  continuation	
  phase	
  of	
  this	
  project,	
  whereby	
  population	
  screenings	
  are	
  organized	
  to	
  detect	
  TB	
  patients	
  in	
  various	
  locations	
  in	
  PNG.	
  The	
  feasibility	
  of	
  active	
  case	
  finding	
  in	
  PNG	
  depends	
  largely	
  on	
  the	
  availability	
  of	
  the	
  necessary	
  staff	
  and	
  infrastructure	
  to	
  conduct	
   such	
   studies,	
   including	
  microscopists	
   and	
  microscopes,	
   sputum	
   storage	
   and	
   transport	
   to	
  Madang	
   for	
   decontamination.	
   Compared	
   to	
   passive	
   case	
   finding,	
   which	
  mimics	
   the	
   usual	
   patient	
  care	
   structure,	
   active	
   case	
   finding	
   requires	
   intensive	
   availability	
   of	
   skilled	
   staff	
   for	
   short	
   periods	
  and	
  at	
  precise	
  locations.	
  This	
  may	
  therefore	
  only	
  be	
  suitable	
  for	
  short	
  term	
  investigations	
  and	
  not	
  for	
  usual	
  care.	
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Implications	
  for	
  tuberculosis	
  control	
  
Drug	
  resistance	
  The	
  observed	
  rates	
  of	
  drug-­‐resistant	
  TB	
  were	
  substantial	
   in	
  the	
  Madang	
  area,	
   indicating	
  that	
  a	
  treatment	
   based	
   on	
   regular	
   first-­‐line	
   drugs	
   cannot	
   guarantee	
   patient	
   cure	
   in	
   all	
   cases.	
   MDR-­‐TB	
  patients	
  require	
  second-­‐line	
  therapies	
  which	
  are	
  long	
  and	
  expensive.	
  Furthermore,	
  patient	
  isolation	
  would	
  be	
  recommendable	
  in	
  case	
  of	
  MDR-­‐TB	
  to	
  limit	
  potential	
  transmission	
  to	
  healthy	
  individuals,	
  but	
  this	
  is	
  seldom	
  feasible	
  in	
  settings	
  like	
  in	
  PNG.	
  Our	
  results	
  indicated	
  that	
  not	
  only	
  RIF	
  and	
  INH	
  resistance	
  were	
  circulating	
  in	
  the	
  Madang	
  area	
  but	
   also	
   STR	
   and	
  ETD.	
  This	
   is	
   useful	
   information	
   for	
   the	
  management	
   of	
   patient	
   treatment	
   since	
  STR	
   is	
   commonly	
  added	
   to	
   first-­‐line	
   regimens	
  when	
  evidence	
   for	
   relapse	
  exists	
   in	
   the	
  absence	
  of	
  DST	
  outcomes.	
  Resistance	
  to	
  ETD	
  (one	
  of	
  the	
  second-­‐line	
  drug	
  option)	
   is	
  often	
  emerging	
  together	
  with	
  INH	
  resistance	
  because	
  both	
  drugs	
  target	
  the	
  same	
  carrier	
  protein	
  reductase	
  (InhA)	
  [109].	
  The	
  risk	
   of	
   cross-­‐resistance	
   indicates	
   that	
   this	
   drug	
   may	
   often	
   not	
   be	
   a	
   good	
   option	
   for	
   second-­‐line	
  therapies,	
  especially	
  in	
  the	
  presence	
  of	
  known	
  inhA	
  promoter	
  mutations.	
  Various	
   aspects	
   of	
   patient	
  management	
   can	
   contribute	
   to	
   the	
  development	
  of	
   drug	
   resistance.	
  Typically,	
   the	
   acquisition	
  of	
   resistance	
   can	
  occur	
  during	
   a	
   treatment	
   course	
   if	
   the	
  drug	
  dosage	
   is	
  sub-­‐optimal,	
  if	
  the	
  drug	
  quality	
  is	
  not	
  as	
  it	
  should	
  be,	
  if	
  compliance	
  to	
  medication	
  is	
  poor	
  or	
  in	
  case	
  of	
  interaction	
  with	
  other	
  drugs	
  reducing	
  treatment	
  efficacy.	
  If	
  these	
  aspects	
  are	
  left	
  unnoticed	
  and	
  if	
  resistance	
   develops,	
   the	
   patient	
   remains	
   infective	
   and	
   transmission	
   of	
   already	
   resistant	
   M.	
  
tuberculosis	
  to	
  other	
  susceptible	
  individuals	
  can	
  occur	
  (primary	
  resistance)	
  in	
  an	
  uncontrolled	
  way.	
  MDR-­‐TB	
   often	
   remains	
   undetected	
   for	
   prolonged	
   periods	
   when	
   DST	
   and	
   other	
   TB	
   diagnostic	
  tools	
  are	
  not	
  readily	
  available	
  on	
  site.	
  And	
  even	
  if	
  available,	
  DST	
  is	
  a	
  lengthy	
  process	
  due	
  to	
  the	
  slow	
  growth	
   rate	
   of	
  M.	
   tuberculosis	
   and	
   patients	
   may	
   be	
   treated	
   with	
   a	
   sub-­‐optimal	
   regimen	
   in	
   the	
  meantime.	
   As	
   an	
   alternative,	
   rapid	
   point-­‐of-­‐care	
   molecular	
   tools	
   applicable	
   on	
   sputum	
   directly	
  would	
  be	
  advantageous	
  in	
  these	
  situations.	
  Ideally,	
  such	
  tools	
  should	
  be	
  easy	
  to	
  perform,	
  fast	
  and	
  cheap.	
  Xpert	
  MTB/RIF	
  (Cepheid,	
  USA)	
  offers	
  a	
  quick	
  and	
  simple	
  way	
  of	
  combining	
  TB	
  diagnosis	
  and	
  RIF	
  resistance	
   test,	
   circumventing	
   the	
  needs	
   for	
  culture	
  or	
  other	
  particular	
   laboratory	
  equipment	
  and	
  know-­‐how	
   [41].	
   The	
   routine	
  use	
  of	
   such	
   tools	
   in	
  PNG	
   could	
  be	
  of	
   immense	
  benefit,	
   allowing	
  drug	
   resistance	
   to	
   be	
   detected	
   already	
   on	
   the	
   first	
   day	
   of	
   clinical	
   visit	
   and	
   therefore	
   to	
   embark	
  directly	
   on	
   adequate	
   therapy	
   if	
   necessary.	
   At	
   the	
   moment,	
   the	
   cost	
   of	
   this	
   technology	
   is	
   still	
  prohibitive	
   for	
   resource-­‐constrained	
   settings	
   like	
   PNG,	
   especially	
   compared	
   to	
   microscopy.	
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However,	
   substantial	
  price	
  reductions	
  are	
  being	
  negotiated	
   to	
  make	
  Xpert	
  MTB/RIF	
  affordable	
   in	
  low-­‐	
   and	
   middle-­‐income	
   countries	
   [41].	
   In	
   early	
   2011,	
   the	
   estimated	
   price	
   per	
   test	
   was	
   still	
  substantially	
  greater	
   than	
   for	
  microscopy,	
  but	
  similar	
   to	
  what	
  culturing	
  and	
  DST	
  cost	
  [41].	
  Faster	
  tests,	
  based	
  for	
  example	
  on	
  a	
  dipstick	
  principle	
  would	
  be	
  ideal,	
  but	
  unfortunately	
  do	
  not	
  exist	
  yet.	
  
Transmission	
  An	
  elevated	
  proportion	
  of	
  molecular	
  clusters	
  was	
  observed	
  in	
  the	
  region	
  of	
  Madang,	
  comprising	
  both	
  drug-­‐susceptible	
  and	
  drug-­‐resistant	
  M.	
  tuberculosis	
  strains.	
  On	
  the	
  one	
  hand,	
  transmission	
  of	
  
M.	
  tuberculosis	
  can	
  occur	
  before	
  active	
  TB	
  is	
  diagnosed,	
  that	
  is	
  when	
  an	
  infectious	
  patient	
  does	
  not	
  know	
  yet	
   about	
  his	
   or	
  her	
   condition	
   and	
   transmits	
  TB	
   to	
  his	
   or	
  her	
   contacts.	
  On	
   the	
  other	
  hand,	
  transmission	
  can	
  occur	
  during	
  the	
  course	
  of	
  treatment,	
  if	
  the	
  prescribed	
  regimen	
  or	
  the	
  adherence	
  is	
  not	
  appropriate	
  and	
  the	
  infection	
  is	
  not	
  cleared	
  efficiently.	
  Active	
  case	
  finding	
  could	
  be	
  a	
  way	
  of	
  reducing	
   transmission	
   by	
   increasing	
   prompt	
   TB	
   diagnosis	
   in	
   the	
   asymptomatic	
   population.	
  Although	
   screening	
   the	
   whole	
   population	
   is	
   not	
   possible,	
   populations	
   at	
   higher	
   risk	
   for	
   TB	
  may	
  need	
   to	
   be	
   targeted	
   first,	
   for	
   example	
   people	
   living	
   or	
   working	
   in	
   particularly	
   crowded	
   places,	
  where	
  transmission	
  is	
  facilitated,	
  or	
  HIV-­‐infected	
  people.	
  When	
  recent	
  transmission	
  can	
  reasonably	
  be	
  ruled	
  out	
  by	
  molecular	
  cluster	
  analysis	
  or	
  contact	
  tracing,	
  the	
  presence	
  of	
  active	
  TB	
  in	
  principle	
  indicates	
  the	
  reactivation	
  of	
  latent	
  TB.	
  It	
  is	
  important	
  to	
  keep	
  in	
  mind	
  that	
  about	
  one	
  third	
  of	
  the	
  world	
  population	
  is	
  latently	
  infected	
  with	
  M.	
  tuberculosis	
  and	
   in	
   average,	
   about	
   10%	
   of	
   these	
   individuals	
   will	
   develop	
   active	
   TB	
   in	
   their	
   lifetime,	
   thereby	
  becoming	
   potential	
   transmitters	
   [21].	
   However,	
   this	
   proportion	
   is	
   higher	
   in	
   some	
   risk	
   groups.	
  Typically,	
  HIV	
   is	
   the	
   strongest	
   known	
   risk	
   factor	
   for	
   TB	
   and	
   co-­‐infected	
   individuals	
   are	
   21	
   to	
   34	
  times	
  more	
  likely	
  to	
  develop	
  active	
  TB	
  [96].	
  The	
  impact	
  of	
  HIV	
  in	
  PNG	
  is	
  certainly	
  not	
  comparable	
  to	
  situations	
  such	
  as	
  observed	
  in	
  Sub-­‐Saharan	
  Africa,	
  although	
  PNG	
  is	
  estimated	
  to	
  be	
  the	
  country	
  with	
  the	
   highest	
   HIV	
   prevalence	
   in	
   Oceania:	
   0.9%	
   [110].	
   Other	
   conditions	
   such	
   as	
   smoking,	
   excessive	
  alcohol	
  consumption,	
  malnutrition,	
  diabetes	
  mellitus	
  or	
  indoor	
  air	
  pollution	
  have	
  also	
  been	
  linked	
  to	
  higher	
  risks	
  of	
  active	
  TB	
  and	
  may	
  be	
  more	
  relevant	
  for	
  PNG	
  [111–113].	
  These	
  risk	
  factors	
  often	
  remain	
  underestimated	
  in	
  the	
  clinical	
  management	
  of	
  patients,	
  but	
  they	
  may	
  silently	
  contribute	
  to	
  higher	
  rates	
  of	
  latent	
  TB	
  activation	
  and	
  thus	
  to	
  potential	
  transmission.	
  Data	
  on	
  the	
  current	
  extent	
  of	
  non-­‐communicable	
  diseases	
  in	
  PNG	
  is	
  scarce	
  and	
  largely	
  relies	
  on	
  estimates	
  with	
  a	
  high	
  degree	
  of	
  uncertainty.	
  However,	
  according	
  to	
  the	
  WHO	
  latest	
  report,	
  13.3%	
  of	
  the	
  Papua	
  New	
  Guineans	
  had	
  a	
  raised	
  blood	
  glucose	
  rate	
  in	
  2008	
  and	
  diabetes	
  was	
  estimated	
  to	
  account	
  for	
  2%	
  of	
  all	
  deaths	
  [114].	
  In	
  fact,	
   the	
  epidemic	
  of	
  type	
  2	
  diabetes	
   is	
  thought	
  to	
  be	
  increasing	
  in	
  PNG,	
  probably	
  as	
  a	
  result	
  of	
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growing	
  westernization	
   and	
  urbanization,	
   and	
  may	
  become	
   a	
  major	
   public	
   health	
   concern	
   in	
   the	
  future	
  [115].	
   In	
  addition,	
  40.9%	
  of	
   the	
  Papua	
  New	
  Guineans	
  declare	
  smoking	
  tobacco	
  daily	
  [114],	
  which	
  could	
  also	
  contribute	
  to	
  higher	
  rates	
  of	
  active	
  TB.	
  	
  
Genetic	
  diversity	
  The	
   genetic	
   diversity	
   observed	
   among	
   the	
   different	
   M.	
   tuberculosis	
   lineages	
   has	
   long	
   been	
  underestimated	
   and	
   yet,	
   such	
   diversity	
   might	
   have	
   implications	
   for	
   the	
   future	
   of	
   TB	
   control.	
   In	
  particular,	
   the	
   strain-­‐to-­‐strain	
   genetic	
   variations	
   may	
   be	
   reflected	
   in	
   the	
   efficacy	
   of	
   newly	
  developed	
   (and	
   urgently	
   needed)	
   diagnostic	
   tools,	
   vaccines	
   or	
   anti-­‐TB	
   drugs.	
   An	
   illustration	
   can	
  already	
  be	
   given	
  by	
   the	
  observed	
  geographical	
   differences	
   in	
  BCG	
  efficacy,	
  which	
   is	
   known	
   to	
  be	
  lower	
  among	
  adults	
  in	
  tropical	
  countries	
  [11].	
  Although	
  several	
  factors	
  may	
  be	
  involved,	
  this	
  poor	
  efficacy	
   might	
   in	
   fact	
   be	
   associated	
   with	
   the	
   phylogeographical	
   differences	
   in	
   M.	
   tuberculosis	
  population	
   structure,	
   whereby	
   different	
   M.	
   tuberculosis	
   lineages	
   predominate	
   in	
   particular	
  geographical	
   regions	
   [73].	
  Although	
   this	
  hypothesis	
  needs	
   confirmation,	
   the	
  development	
  of	
   new	
  vaccines	
  should	
  take	
  into	
  account	
  that	
  genetic	
  differences	
  among	
  M.	
  tuberculosis	
  lineages	
  exist,	
  and	
  that	
  implications	
  on	
  the	
  global	
  efficacy	
  of	
  vaccine	
  candidates	
  may	
  occur	
  [68].	
  The	
  genetic	
  diversity	
  of	
  M.	
  tuberculosis	
   could	
  also	
   impair	
  diagnostic	
   tools	
  relying	
  on	
  particular	
  DNA	
  sequences,	
  which	
  may	
  not	
  be	
  conserved	
  throughout	
  all	
  lineages.	
  Furthermore,	
  diagnostic	
  tests	
  based	
   on	
   antigen-­‐specific	
   immune	
   response	
  may	
   not	
   perform	
   equally	
  well	
   for	
   all	
  M.	
   tuberculosis	
  lineages,	
   as	
   suggested	
   by	
   a	
   study	
   in	
   The	
   Gambia,	
   showing	
   that	
   the	
   T-­‐cell	
   response	
   to	
   particular	
  MTBC	
   antigens	
   varied	
   among	
   lineages	
   [68,116].	
   Such	
   lineage-­‐dependant	
   differences	
   in	
   immune	
  response	
  may	
  not	
  only	
  have	
  implications	
  for	
  the	
  development	
  of	
  serologic	
  diagnostic	
  tests,	
  but	
  also	
  for	
   vaccine	
   candidates,	
   which	
   should	
   prevent	
   M.	
   tuberculosis	
   infections	
   regardless	
   of	
   intrinsic	
  genetic	
  variations.	
  	
  Regarding	
  anti-­‐TB	
  drugs,	
  a	
  famous	
  difference	
  resulting	
  from	
  the	
  MTBC	
  genetic	
  variation	
  is	
  given	
  by	
  the	
  intrinsic	
  resistance	
  of	
  M.	
  bovis	
  to	
  PZA,	
  which	
  is	
  caused	
  by	
  a	
  constitutive	
  mutation	
  in	
  the	
  gene	
  
pncA	
  [117].	
  Similarly,	
  other	
  existing	
  lineage-­‐specific	
  mutations	
  may	
  also	
  play	
  a	
  role	
  in	
  intrinsic	
  drug	
  resistances	
   and	
   this	
  may	
   need	
   to	
   be	
   considered	
   for	
   the	
   development	
   of	
   new	
   anti-­‐TB	
   compounds	
  [68].	
   In	
  addition,	
  M.	
  tuberculosis	
   strains	
  belonging	
  to	
   the	
  East-­‐Asian	
   lineage	
  have	
  repeatedly	
  been	
  associated	
  with	
  drug-­‐resistance	
   [118],	
   as	
   reflected	
  by	
  our	
  observations	
   in	
  PNG.	
  Furthermore,	
   the	
  genetic	
  background	
  of	
  M.	
  tuberculosis	
  was	
  also	
  shown	
  to	
  influence	
  the	
  propensity	
  of	
  drug-­‐resistant	
  strains	
  to	
  spread	
  effectively	
  [119].	
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Outlook	
  This	
  thesis	
  provided	
  the	
  first	
  contribution	
  about	
  the	
  molecular	
  epidemiology	
  of	
  TB	
  in	
  PNG	
  and	
  initiated	
   future	
   research	
   projects	
   on	
   this	
   topic.	
   Since	
   2010,	
   five	
   additional	
   sites	
   in	
   highland	
   and	
  coastal	
   locations	
  were	
  selected	
  to	
  expand	
  TB	
  research	
   in	
  PNG	
  with	
  an	
  approach	
  combining	
  active	
  and	
  passive	
  TB	
  case	
  finding.	
  	
  In	
   this	
   section,	
   perspectives	
   about	
   possible	
   research	
   questions	
   left	
   unanswered	
   by	
   this	
   thesis	
  and	
  about	
  the	
  future	
  of	
  TB	
  control	
  in	
  PNG	
  are	
  discussed.	
  
Open	
  questions	
  related	
  to	
  strain	
  genotypes	
  The	
   genotyping	
   of	
   the	
   strains	
   collected	
   in	
   the	
   frame	
   of	
   this	
   project	
   indicated	
   the	
   presence	
   of	
  mainly	
  two	
  of	
  the	
  six	
  global	
  lineages	
  of	
  human-­‐adapted	
  M.	
  tuberculosis	
  described	
  previously	
  [7,73].	
  One	
   interesting	
   aspect	
   of	
   these	
   lineages	
   is	
   their	
   close	
   association	
  with	
   geographical	
   regions	
   and	
  their	
   preferential	
   occurrence	
   among	
   hosts	
   originating	
   from	
   each	
   of	
   these	
   regions	
   [73].	
   The	
   two	
  predominant	
  M.	
   tuberculosis	
   lineages	
   observed	
   among	
   Papua	
  New	
  Guineans	
   in	
   the	
  Madang	
   area,	
  Lineage	
  2	
  and	
  4,	
  are	
  also	
  called	
  East-­‐Asian	
  and	
  Euro-­‐American	
  for	
  the	
  regions	
  where	
  they	
  prevail.	
  The	
  predominance	
  of	
  Euro-­‐American	
  and	
  East-­‐Asian	
  M.	
  tuberculosis	
  lineages	
  in	
  the	
  Madang	
  region	
  could	
   indicate	
  that	
  the	
   introduction	
  of	
  TB	
  in	
  this	
  area	
   is	
   fairly	
  recent	
  and	
  might	
  coincide	
  with	
  the	
  various	
  waves	
  of	
  successive	
  colonization	
  during	
  the	
  last	
  centuries.	
  Along	
  these	
  lines,	
  Lineage	
  4	
  M.	
  
tuberculosis	
   strains	
   (i.e.	
   Euro-­‐American	
   lineage)	
   could	
   have	
   been	
   brought	
   to	
   PNG	
   by	
   Spanish	
   or	
  Portuguese	
  migrants	
  in	
  the	
  16th	
  century;	
  or	
  possibly	
  later	
  when	
  English	
  settled	
  in	
  PNG	
  at	
  the	
  end	
  of	
  the	
   19th	
   century,	
   followed	
   by	
   Australians	
   and	
   Germans	
   at	
   the	
   beginning	
   of	
   the	
   20th	
   century.	
   In	
  addition,	
   many	
   groups	
   of	
   missionaries	
   of	
   European	
   origin	
   have	
   settled	
   in	
   various	
   locations	
  throughout	
  PNG	
   in	
   the	
   last	
  decades	
  and	
  may	
  also	
  have	
  contributed	
   to	
   the	
  spread	
  of	
  Lineage	
  4	
  M.	
  
tuberculosis	
   strains.	
   On	
   the	
   other	
   hand,	
   Lineage	
   2	
  M.	
   tuberculosis	
   strains	
   (i.e.	
   East-­‐Asian	
   lineage)	
  predominate	
   in	
  Asia	
   and	
  one	
   could	
  hypothesize	
   that	
   they	
  were	
  brought	
   to	
   PNG	
   in	
  parallel	
   to	
   the	
  important	
  immigration	
  of	
  Chinese	
  laborers	
  and	
  traders	
  in	
  the	
  last	
  decades.	
  	
  The	
  waves	
  of	
  migrations	
  described	
  above	
  may	
  not	
  have	
  reached	
  all	
  regions	
  of	
  PNG	
  to	
  the	
  same	
  extent,	
   and	
   this	
  may	
  be	
   reflected	
  by	
   regional	
  differences	
   in	
  M.	
   tuberculosis	
   genotype	
  distribution.	
  For	
   instance,	
   it	
   is	
   well	
   possible	
   that	
   Chinese	
   populations	
   are	
   particularly	
   concentrated	
   in	
   urban	
  regions	
  or	
  around	
  mines	
  and	
  less	
  present	
  in	
  some	
  rural	
  regions	
  of	
  PNG.	
  Such	
  variations	
  might	
  result	
  in	
  higher	
  proportions	
  of	
   the	
  East-­‐Asian	
   lineage	
  of	
  M.	
   tuberculosis	
   in	
   these	
   locations.	
   Similarly,	
  we	
  also	
  know	
  that	
  missionaries	
  (generally	
  from	
  European	
  origin)	
  tended	
  to	
  be	
  more	
  numerous	
  in	
  the	
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coastal	
   regions,	
   which	
   were	
   initially	
   more	
   easily	
   reached	
   than	
   the	
   highlands.	
   It	
   is	
   nevertheless	
  possible	
   that	
   because	
   road	
   and	
   air	
   travel	
   across	
  PNG	
  has	
   become	
   easier	
   in	
   the	
  past	
   decades,	
   the	
  actual	
   regional	
  differences	
  which	
  could	
  have	
  been	
  observed	
  are	
  now	
   faded.	
  Only	
  when	
  data	
   from	
  various	
   locations	
   throughout	
   PNG	
   will	
   be	
   available,	
   will	
   we	
   be	
   able	
   to	
   better	
   assess	
   these	
  hypotheses.	
  Yet,	
  if	
  different	
  M.	
  tuberculosis	
  genotype	
  distributions	
  are	
  seen	
  in	
  particular	
  regions	
  of	
  PNG,	
  one	
  could	
   alternatively	
   hypothesize	
   that	
   these	
   differences	
   mimic	
   the	
   high	
   genetic	
   variation	
   found	
  among	
   indigenous	
   PNG	
   populations.	
   Indeed,	
   PNG	
   has	
   fascinated	
   many	
   researchers	
   in	
   the	
   past	
  decades,	
   especially	
   anthropologists	
   and	
   linguists	
   who	
   were	
   attracted	
   by	
   the	
   great	
   socio-­‐cultural	
  diversity	
   condensed	
   in	
   this	
   country,	
   where	
   some	
   populations	
   evolved	
   over	
   centuries	
   with	
   very	
  limited	
  contacts	
  to	
  the	
  outside	
  world.	
  Linguists	
  have	
  identified	
  more	
  than	
  800	
  different	
  Papuan	
  and	
  Austronesian	
  languages	
  in	
  PNG,	
  associated	
  with	
  two	
  separated	
  waves	
  of	
  immigration	
  expanding	
  in	
  PNG	
  about	
  6,000-­‐10,000	
  years	
  ago	
  and	
  about	
  3,300	
  years	
  ago,	
  respectively	
  [104,120].	
  Furthermore,	
  molecular	
   analyses	
   showed	
   a	
   great	
   genetic	
   diversity	
   among	
   PNG	
   indigenous	
   populations,	
  particularly	
   marked	
   by	
   a	
   reduced	
   variation	
   within	
   population	
   but	
   a	
   high	
   divergence	
   between	
  populations.	
   The	
  most	
   divergent	
   populations	
   were	
   seen	
   in	
   the	
   rugged	
   interiors	
   of	
   large	
   islands,	
  which	
   are	
   believed	
   to	
   host	
   population	
   groups	
   of	
   older	
   origin	
   [104,120].	
   If	
   the	
   indigenous	
  populations	
  living	
  in	
  the	
  mountainous	
  regions	
  of	
  PNG	
  (i.e.	
  PNG	
  Highlanders)	
  are	
  genetically	
  distinct	
  from	
  the	
  populations	
  living	
  on	
  the	
  coast,	
  it	
  could	
  be	
  worth	
  exploring	
  whether	
  this	
  difference	
  would	
  also	
  be	
  reflected	
  in	
  the	
  genotypic	
  profiles	
  of	
  the	
  infecting	
  M.	
  tuberculosis	
  populations.	
  In	
   addition,	
   interesting	
   comparisons	
   could	
   be	
   done	
   if	
   M.	
   tuberculosis	
   genotypic	
   data	
   from	
  neighboring	
  regions	
  were	
  available.	
  This	
  could	
  for	
  instance	
  include	
  data	
  about	
  strains	
  collected	
  in	
  Australia,	
   other	
  Melanesian	
   countries	
  or	
  Papua,	
   the	
   Indonesian	
  province	
   sharing	
  border	
  with	
   the	
  PNG	
   mainland.	
   Also	
   interesting	
   would	
   be	
   to	
   explore	
   the	
   M.	
   tuberculosis	
   genotypes	
   circulating	
  among	
  indigenous	
  Australians,	
  who	
  are	
  genetically	
  related	
  to	
  PNG	
  highlanders	
  [121].	
  
Open	
  questions	
  related	
  to	
  the	
  burden	
  of	
  TB	
  in	
  PNG	
  The	
   extent	
   of	
   the	
   current	
   TB	
   epidemic	
   in	
   PNG	
   remains	
   largely	
   unknown	
   und	
   epidemiological	
  data	
   is	
  scarce.	
  There	
   is	
  some	
  anecdotal	
  evidence	
  suggesting	
   that	
   the	
  prevalence	
  of	
  pulmonary	
  TB	
  would	
  be	
  lower	
  in	
  the	
  highlands	
  than	
  in	
  the	
  lowlands	
  of	
  PNG,	
  but	
  further	
  investigations	
  are	
  needed	
  to	
   confirm	
   this	
   difference	
   and	
   identify	
   the	
   potential	
   reasons	
   for	
   it.	
   Also	
   to	
   be	
   explored	
   are	
   the	
  potential	
  explanations	
  for	
  the	
  observed	
  large	
  difference	
  in	
  drug	
  resistance	
  rates	
  observed	
  between	
  the	
  Western	
  Province	
  (25.0%	
  MDR-­‐TB	
  [102])	
  and	
  the	
  Madang	
  region	
  (5.2%	
  MDR-­‐TB).	
  One	
  reason	
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could	
  be	
  that	
  the	
  proximity	
  of	
  Australian	
  health	
  facilities	
  may	
  have	
  biased	
  the	
  study	
  population	
  in	
  Western	
   Province	
   towards	
   sicker	
   individuals,	
   potentially	
   seeking	
   better	
   treatment	
   in	
   Australian	
  territories,	
   where	
   second-­‐line	
   drugs	
   are	
   more	
   readily	
   available	
   (Coulter	
   C.,	
   personal	
  communication).	
  Differences	
   in	
  TB	
  prevalence	
  or	
   in	
  MDR-­‐TB	
  rates	
  are	
   to	
  be	
  expected	
   throughout	
  PNG	
  and	
  data	
  from	
  multiple	
  sites	
  would	
  provide	
  the	
  necessary	
  baseline	
  information	
  to	
  investigate	
  these	
  aspects.	
  	
  Learning	
   from	
   the	
   limitations	
   of	
   the	
   present	
   study	
   (see	
   section	
   above),	
   future	
   investigations	
  could	
  include	
  active	
  case	
  finding	
  and	
  thereby	
  increase	
  access	
  to	
  TB	
  diagnosis	
  among	
  populations	
  at	
  risk.	
   Indeed,	
   active	
   case	
   finding	
   approaches	
   can	
   contribute	
   to	
   reduce	
   the	
   delay	
   before	
   treatment	
  initiation,	
  when	
  the	
  risk	
  of	
  M.	
  tuberculosis	
  transmission	
  to	
  susceptible	
  contacts	
  is	
  the	
  highest;	
  a	
  risk	
  which	
   can	
   be	
   particularly	
   enhanced	
   in	
   developing	
   countries,	
   where	
   a	
   larger	
   fraction	
   of	
   M.	
  
tuberculosis	
  infected	
  people	
  tends	
  to	
  develop	
  active	
  TB	
  [57].	
  	
  
The	
  future	
  of	
  TB	
  control	
  in	
  PNG	
  Efforts	
  need	
  to	
  be	
  sustained	
  to	
  achieve	
  a	
  long	
  term	
  decrease	
  of	
  the	
  TB	
  burden	
  in	
  PNG.	
  In	
  addition	
  to	
   the	
  monitoring	
   of	
   treatment	
   success	
   performed	
   in	
   the	
   frame	
   of	
   the	
   treatment	
   cohort	
   study	
   in	
  Madang,	
   stronger	
   investigations	
   about	
   TB	
   history	
   and	
   potential	
   transmission	
   foci	
  would	
   provide	
  valuable	
  information	
  to	
  identify	
  where	
  future	
  efforts	
  should	
  be	
  put	
  to	
  better	
  curb	
  TB	
  in	
  PNG.	
  Recently,	
  Ongugo	
  et	
  al.	
  reviewed	
  the	
  possible	
  drawbacks	
  that	
  could	
  impair	
  the	
  success	
  of	
  DOTS	
  in	
  PNG	
  [122].	
  According	
  to	
  the	
  authors,	
  it	
  is	
  important	
  that	
  the	
  PNG	
  government	
  better	
  supports	
  the	
  extension	
  of	
  DOTS	
  with	
  a	
  particular	
  attention	
  on	
  overcrowded	
  settlements,	
  which	
  are	
  prone	
  to	
  TB	
  outbreaks	
   and	
   on	
   rural	
   areas,	
   where	
   access	
   to	
   health	
   care	
   is	
   limited	
   due	
   to	
   the	
   geographical	
  constrains.	
   An	
   increased	
   rate	
   of	
   disease	
   detection	
   is	
   also	
   particularly	
   important	
   and	
   can	
   only	
   be	
  achieved	
   if	
   good	
   diagnostic	
   tools	
   are	
   available	
   together	
   with	
   well	
   trained	
   staff	
   to	
   perform	
   the	
  diagnosis	
   adequately.	
   In	
   parallel,	
   TB	
   awareness	
   is	
   essential	
   among	
   the	
   general	
   community	
   and	
  among	
  medical	
  workers	
  in	
  order	
  to	
  help	
  reducing	
  delays	
  between	
  symptom	
  onset	
  and	
  TB	
  diagnosis,	
  thereby	
  decreasing	
   the	
   risks	
  of	
   transmission.	
  Furthermore,	
   the	
  directly	
  observed	
   therapy	
  aims	
  at	
  limiting	
   adherence	
   problems	
   and	
   should	
   be	
   particularly	
   encouraged	
   upon	
   anti-­‐TB	
   treatment	
  initiation.	
  Fixed-­‐dose	
  drug	
  combinations	
  are	
  also	
  a	
  way	
  of	
   increasing	
  compliance	
  by	
  reducing	
   the	
  pill	
   burden	
   and	
   should	
   be	
   considered	
   whenever	
   possible.	
   But	
   importantly,	
   Ongugo	
   et	
   al.	
  recommended	
   that	
   reliable	
   first-­‐	
   and	
   second-­‐line	
   drugs	
   should	
   be	
   available	
   in	
   a	
   controlled	
   way	
  among	
   clinics	
   throughout	
   the	
   country	
   [122].	
   Coupled	
   to	
   prompt	
   resistance	
   testing,	
   this	
   should	
  prevent	
   the	
   expansion	
   of	
   MDR-­‐TB	
   in	
   PNG.	
   Nevertheless,	
   the	
   future	
   of	
   TB	
   control	
   may	
   not	
   only	
  
GENERAL	
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concern	
   clinical	
   interventions	
   but	
   may	
   also	
   need	
   to	
   integrate	
   economic,	
   social	
   and	
   educational	
  actions	
  in	
  a	
  comprehensive	
  approach	
  aiming	
  at	
  halting	
  the	
  spread	
  of	
  TB	
  in	
  PNG	
  [123].	
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